A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Significant improvements in the management of hepatocellular carcinoma (HCC) during the past three years have urged the timely update of clinical guidelines in China. In brief, aMAP score is newly recommended as an effective risk stratification tool to predict HCC occurrence especially for non-cirrhotic patients. Biomarker-based surveillance including 7 micro-RNA panel and GALAD score are advocated to assist early diagnosis. China liver cancer (CNLC) staging system proposed in the 2017 guideline continues to be the standard model for staging with modifications in the treatment allocations. Conversion therapies using multi-modal, high intensity strategies are advocated to facilitate subsequent resection for patients with technically unresectable CNLC stage Ia, Ib, IIa HCC, or technically resectable IIb, IIIa HCC. Super-selective transcatheter arterial chemoembolization (TACE) with the assistance of Cone-Beam CT if necessary is recommended to guarantee the efficacy of TACE. Hepatic arterial infusion chemotherapy (HAIC) using oxaliplatin, fluorouracil, and leucovorin (FOLFOX) regimen alone or in combination with systemic therapy is recommended for TACE-refractory patients or for patients with locally advanced HCC. The systemic treatments for HCC have evolved considerably since atezolizumab plus bevacizumab, and suntilimab plus bevacizumab analogue showing superior survival benefit to sorafenib, and donafenib with comparable efficacy with sorafenib are added to the first-line treatments. In addition to regorafenib, apatinib, camrelizumab and tislelizumab are added as the second-line systemic therapies for patients who progressed on sorafenib. Updates in the 2022 Barcelona Clinic Liver Cancer (BCLC) guidelines and Japanese Society of Hepatology (JSH) consensus statement are also introduced and compared with the 2022 Chinese guidelines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
Zhou, M., Wang, H., Zeng, X., Yin, P., Zhu, J., Chen, W., Li, X., Wang, L., Wang, L., Liu, Y., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30427-1 · Cited by 3,639
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344 · cited 1×
“Cabozantinib is also effective in the third-line setting (88).”
Yao, F. Y., Ferrell, L., Bass, N. M., Watson, J. J., Bacchetti, P., Venook, A., Ascher, N. L., & Roberts, J. P. (2001) · Hepatology · doi:10.1053/jhep.2001.24563 · Cited by 2,262 · cited 1×
“Considering shortage of liver donors, University of California San Francisco (UCSF) criteria (solitary tumor ≤ 6.5 cm or ≤ 3 nodules ≤ 4.5 cm plus total tumor diameter ≤ 8 cm) continues to be advocated for wide application in China (43).”
InfluentialRelatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109970 · Cited by 1,883
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843 · cited 1×
“Currently, more than 20 phase III trials are undergoing to identify the role of ICI-based therapies across all stages of HCC (97).”
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Park, J., Chen, M., Colombo, M., Roberts, L. R., Schwartz, M., Chen, P., Kudo, M., Johnson, P., Wagner, S., Orsini, L. S., et al. (2015) · Liver International · doi:10.1111/liv.12818 · Cited by 1,245 · cited 1×
“…cases were initially diagnosed at intermediate and advanced stages respectively, whereas in Japan and north America, the percentages of patients diagnosed at intermediate stage were 10% and 14%, and those diagnosed at advanced stage were 42% and 12% respectively according to the BRIDGE study (4).”
Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00252-7 · Cited by 1,124
Self-citationBruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120 · cited 1×
“The STROM trial frustrates the usage of sorafenib as adjuvant therapy (38).”
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.007 · Cited by 976
Kudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., Izumi, N., Yamasaki, T., Nojiri, S., Hino, K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-318934 · Cited by 721 · cited 2×
“Various clinical trials have been conducted to evaluate the efficacy of TACE in combination with sorafenib for BCLC B HCC (68-71), but only one study warrant such combination therapy (71).”
InfluentialLencioni, R., Llovet, J. M., Han, G., Tak, W. Y., Yang, J., Guglielmi, A., Paik, S. W., Reig, M., Kim, D. Y., Chau, G.-Y., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.012 · Cited by 694 · cited 1×
“Various clinical trials have been conducted to evaluate the efficacy of TACE in combination with sorafenib for BCLC B HCC (68-71), but only one study warrant such combination therapy (71).”
Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer · doi:10.1159/000514174 · Cited by 678 · cited 1×
“The Barcelona Clinic Liver Cancer (BCLC) group and the Japanese Society of Hepatology (JSH) have also updated recommendations on the staging and treatment allocations of HCC recently (5,6).”
Mazzaferro, V., Sposito, C., Zhou, J., Pinna, A. D., De Carlis, L., Fan, J., Cescon, M., Di Sandro, S., Yi-feng, H., Lauterio, A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.09.025 · Cited by 655 · cited 1×
“Although the morphological criteria for defining transplant feasibility among this BCLC B subgroup has not been reached, AFP >1,000 ng/mL, as a surrogate reflecting invasive tumor biology, is set as a contraindication for LT in the 2022 BCLC guidelines (47,48).”
Self-citationMELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era
Kim, W. R., Mannalithara, A., Heimbach, J. K., Kamath, P. S., Asrani, S. K., Biggins, S. W., Wood, N. L., Gentry, S. E., & Kwong, A. J. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.08.050 · Cited by 642
Plasma MicroRNA Panel to Diagnose Hepatitis B Virus–Related Hepatocellular Carcinoma
Zhou, J., Yu, L., Gao, X., Hu, J., Wang, J., Dai, Z., Wang, J.-F., Zhang, Z., Lu, S., Huang, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2697 · Cited by 635
Self-citationQin, S., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., Zhu, H., Fang, W., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30011-5 · Cited by 602 · cited 1×
“Apart from regorafenib, targeted agent apatinib (80) and PD-1 inhibitors camrelizumab (85) and tislelizumab (86,87) are added as second-line systemic therapies for patients who progressed on sorafenib in the 2022 Chinese guidelines.”
Self-citationKudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.-Y., Takayama, T., Yoon, J.-H., Hori, T., Kumada, H., Hayashi, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.007 · Cited by 570
He, M., Li, Q., Zou, R., Shen, J., Fang, W., Tan, G., Zhou, Y., Wu, X., Xu, L., Wei, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0250 · Cited by 548
[The guidelines of prevention and treatment for chronic hepatitis B (2019 version)].
(2019) · PubMed Central · doi:10.3760/cma.j.issn.1007-3418.2019.12.007 · Cited by 500 · cited 1×
“Apart from anti-tumor therapies, antiviral therapies with entecavir, tenofovir or tenofovir alafenamide fumarate are recommended for patients with detectable HBV-DNA or positive hepatitis B surface antigen (HBsAg) through the entire duration of treatment for HCC (93).”
Meyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M. W., Sturgess, R., Stubbs, C., Stocken, D. D., Wall, L., Watkinson, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30156-5 · Cited by 499
Kokudo, T., Hasegawa, K., Matsuyama, Y., Takayama, T., Izumi, N., Kadoya, M., Kudo, M., Ku, Y., Sakamoto, M., Nakashima, O., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.044 · Cited by 491 · cited 1×
“…vein or hepatic vein invasion, hepatectomy is suggested in Asian countries as propensity score matched (PSM) studies have shown improved survival benefit for patients undergoing resection compared to those receiving other treatments including intra-arterial therapies or chemotherapies (19,20).”
Travis, W. D., Dacic, S., Wistuba, I., Sholl, L., Adusumilli, P., Bubendorf, L., Bunn, P., Cascone, T., Chaft, J., Chen, G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.005 · Cited by 465 · cited 1×
“…response (MPR) defined as the remnant alive tumor ≤ 10% and complete pathological response (CPR) defined as complete necrosis of the tumor indicating favorable prognosis in other types of cancer may be equally applicable for HCC (32,33), the result of which need more studies for confirmation.”
Pinato, D. J., Sharma, R., Allara, E., Yen, C., Arizumi, T., Kubota, K., Bettinger, D., Jang, J. W., Smirne, C., Kim, Y. W., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.008 · Cited by 413
Qin, S., Bi, F., Gu, S., Bai, Y., Chen, Z., Wang, Z., Ying, J., Lu, Y., Meng, Z., Pan, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00163 · Cited by 409 · cited 1×
“Apart from regorafenib, targeted agent apatinib (80) and PD-1 inhibitors camrelizumab (85) and tislelizumab (86,87) are added as second-line systemic therapies for patients who progressed on sorafenib in the 2022 Chinese guidelines.”
Self-citation[Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)].
(2022) · PubMed Central · doi:10.3760/cma.j.cn501113-20221204-00607 · Cited by 405
Abou-Alfa, G. K., Chan, S. L., Kudo, M., Lau, G., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Dao, T. V., De Toni, E. N., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.379 · Cited by 388 · cited 2×
“Recently, experiences from Europe and North America have verified the superiority of hepatectomy over sorafenib for patients with locally advanced HCC (21,22).”
Berzigotti, A., Reig, M., Abraldes, J. G., Bosch, J., & Bruix, J. (2015) · Hepatology · doi:10.1002/hep.27431 · Cited by 385 · cited 1×
“On the other hand, the BCLC group insist on only patients with solitary HCC in the absence of clinically significant portal hypertension (CSPH) as optimal target population for hepatectomy (36).”
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.004 · Cited by 380 · cited 9×
“The advent of systemic treatments like Atezo-Bev with marked survival benefit encourages a shift of application to earlier stage in the BCLC guidelines, whereas more aggressive multimodal treatments like the addition of immunotherapy-based systemic treatment to local therapies are proposed in Chinese guidelines.”
InfluentialaMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., Mo, S., Sypsa, V., Guha, I. N., Kumada, T., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.025 · Cited by 364 · cited 1×
“The aMAP (age-Male-ALBI-Platelets) scoring system (9) as an effective quantitative risk stratification tool to predict HCC occurrence irrespective of etiology and ethnicity is newly recommended in the updated Chinese guidelines.”
Mazzaferro, V., Citterio, D., Bhoori, S., Bongini, M., Miceli, R., De Carlis, L., Colledan, M., Salizzoni, M., Romagnoli, R., Antonelli, B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30224-2 · Cited by 341
Wang, Z., Ren, Z., Chen, Y., Hu, J., Yang, G., Yu, L., Yang, X., Huang, A., Zhang, X., Zhou, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2899 · Cited by 318 · cited 1×
“For patients with intermediate risk (single nodule >5 cm without microvascular invasion) or high risk (single nodule >5 cm with microvascular invasion, multiple nodules) for recurrence, TACE has been established as an effective adjuvant therapy in China (39).”
Self-citationKudo, M., Ueshima, K., Chan, S., Minami, T., Chishina, H., Aoki, T., Takita, M., Hagiwara, S., Minami, Y., Ida, H., et al. (2019) · Cancers · doi:10.3390/cancers11081084 · Cited by 309 · cited 1×
“For TACE-unsuitable HCC, the JSH recommend a lenvatinib-TACE sequential therapy based on a proof-of-concept study (66,67).”
Kudo, M., Ueshima, K., Yokosuka, O., Ogasawara, S., Obi, S., Izumi, N., Aikata, H., Nagano, H., Hatano, E., Sasaki, Y., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30078-5 · Cited by 305 · cited 8×
“Hepatectomy, as a major curative treatment, is preferably indicated for patients with CNLC stage Ia, Ib and IIa HCC, the criteria of which is consistent with that in Japan.”
InfluentialKulik, L., Heimbach, J. K., Zaiem, F., Almasri, J., Prokop, L. J., Wang, Z., Murad, M. H., & Mohammed, K. (2018) · Hepatology · doi:10.1002/hep.29485 · Cited by 298 · cited 1×
“For patients on the waiting list for LT, the efficacy of bridging therapies via locoregional or systemic therapies to prevent tumor progression remains controversial (51,52).”
Best, J., Bechmann, L. P., Sowa, J.-P., Sydor, S., Dechêne, A., Pflanz, K., Bedreli, S., Schotten, C., Geier, A., Berg, T., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.11.012 · Cited by 288
Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
Kudo, M., Matsui, O., Izumi, N., Kadoya, M., Okusaka, T., Miyayama, S., Yamakado, K., Tsuchiya, K., Ueshima, K., Hiraoka, A., et al. (2014) · Oncology · doi:10.1159/000368142 · Cited by 283 · cited 1×
“…range of effective systemic therapies, patients who experience Untreatable Progression (UTP) under TACE defined as failure of TACE (63) by the BCLC group, or TACE refractoriness defined as no response after two TACE sessions (64) by the JSH are recommended to switch to systemic therapies (65).”
Lyu, N., Kong, Y., Mu, L., Lin, Y., Li, J., Liu, Y., Zhang, Z., Zheng, L., Deng, H., Li, S., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.02.008 · Cited by 281
Hameed, B., Mehta, N., Sapisochin, G., Roberts, J. P., & Yao, F. Y. (2014) · Liver Transplantation · doi:10.1002/lt.23904 · Cited by 279 · cited 1×
“Although the morphological criteria for defining transplant feasibility among this BCLC B subgroup has not been reached, AFP >1,000 ng/mL, as a surrogate reflecting invasive tumor biology, is set as a contraindication for LT in the 2022 BCLC guidelines (47,48).”
Wang, Q., Xia, D., Bai, W., Wang, E., Sun, J., Huang, M., Mu, W., Yin, G., Li, H., Zhao, H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.013 · Cited by 261 · cited 1×
“Besides the previous “six-and-twelve” scoring system (60), “Pre-TACE-Predict” model using tumor number, size, AFP, albumin, bilirubin, vascular invasion and etiology, and “Post-TACE-Predict” model using number, size, AFP, bilirubin, vascular invasion and imaging response are proposed to predict the…”
Consensus Guidelines for the Use of Fluorescence Imaging in Hepatobiliary Surgery
Wang, X., Teh, C. S. C., Ishizawa, T., Aoki, T., Cavallucci, D., Lee, S.-Y., Panganiban, K. M., Perini, M. V., Shah, S. R., Wang, H., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000004718 · Cited by 256 · cited 1×
“Technically, fluorescence imaging with indocyanine green (ICG) facilitating tumor imaging and delineation of segmental boundaries has been advocated to secure R0 resection (16).”
Zhu, X.-D., Huang, C., Shen, Y.-H., Ji, Y., Ge, N.-L., Qu, X.-D., Chen, L., Shi, W.-K., Li, M.-L., Zhu, J.-J., et al. (2021) · Liver Cancer · doi:10.1159/000514313 · Cited by 234 · cited 1×
“Systemic therapies like tyrosine kinase inhibitors (TKIs) plus programmed death-1 (PD-1) inhibitors (24-27), locoregional treatments including TACE, hepatic arterial infusion chemotherapy (HAIC) using oxaliplatin, fluorouracil, and leucovorin regimen (FOLFOX-HAIC), or TACE plus FOLFOX-HAIC (28),…”
Self-citationKim, T. H., Koh, Y. H., Kim, B. H., Kim, M. J., Lee, J. H., Park, B., & Park, J.-W. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.026 · Cited by 230
Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma
Pinna, A. D., Yang, T., Mazzaferro, V., De Carlis, L., Zhou, J., Roayaie, S., Shen, F., Sposito, C., Cescon, M., Di Sandro, S., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002889 · Cited by 226 · cited 1×
“Postoperative recurrence occurs in up to 80% of patients (37) .”
Self-citationMehta, N., Bhangui, P., Yao, F. Y., Mazzaferro, V., Toso, C., Akamatsu, N., Durand, F., Ijzermans, J., Polak, W., Zheng, S., et al. (2020) · Transplantation · doi:10.1097/tp.0000000000003174 · Cited by 221 · cited 1×
“There is a growing global consensus on that a minor increase in tumor size and number beyond Milan criteria does not withdraw the long-term survival benefit of LT (44-46).”
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
Alliance of Liver Cancer Conversion Therapy, C. O. L. C. O. T. C. A.-C. A., Sun, H.-C., Zhou, J., Wang, Z., Liu, X., Xie, Q., Jia, W., Zhao, M., Bi, X., Li, G., et al. (2022) · Hepatobiliary Surgery and Nutrition · doi:10.21037/hbsn-21-328 · Cited by 206
Self-citationKim, N., Cheng, J., Jung, I., Liang, J. D., Shih, Y. L., Huang, W.-Y., Kimura, T., Lee, V. H. F., Zeng, Z. C., Zhenggan, R., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.005 · Cited by 200 · cited 1×
“According to several retrospective studies, stereotactic body radiation therapy (SBRT) showed comparable survival benefit with radiofrequency ablation (RFA) for early-stage HCC (55,56).”
Kokudo, T., Hasegawa, K., Matsuyama, Y., Takayama, T., Izumi, N., Kadoya, M., Kudo, M., Kubo, S., Sakamoto, M., Nakashima, O., et al. (2017) · Hepatology · doi:10.1002/hep.29225 · Cited by 195 · cited 1×
“…vein or hepatic vein invasion, hepatectomy is suggested in Asian countries as propensity score matched (PSM) studies have shown improved survival benefit for patients undergoing resection compared to those receiving other treatments including intra-arterial therapies or chemotherapies (19,20).”
Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
Stein, J. E., Lipson, E. J., Cottrell, T. R., Forde, P. M., Anders, R. A., Cimino-Mathews, A., Thompson, E. D., Allaf, M. E., Yarchoan, M., Feliciano, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2379 · Cited by 177 · cited 1×
“…response (MPR) defined as the remnant alive tumor ≤ 10% and complete pathological response (CPR) defined as complete necrosis of the tumor indicating favorable prognosis in other types of cancer may be equally applicable for HCC (32,33), the result of which need more studies for confirmation.”
Keam, S. J. (2022) · Drugs · doi:10.1007/s40265-022-01761-9 · Cited by 172
Aoki, T., Kokudo, N., Matsuyama, Y., Izumi, N., Ichida, T., Kudo, M., Ku, Y., Sakamoto, M., Nakashima, O., Matsui, O., et al. (2014) · Annals of Surgery · doi:10.1097/sla.0b013e31828846de · Cited by 167
Singal, A. G., Hoshida, Y., Pinato, D. J., Marrero, J., Nault, J.-C., Paradis, V., Tayob, N., Sherman, M., Lim, Y. S., Feng, Z., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.01.233 · Cited by 164 · cited 1×
“Instead, preserved liver function is advocated and evaluated via comprehensive evaluation of Albumin-Bilirubin (ALBI) score (12), Child-Pugh score, model for end-stage liver disease (MELD) 3.0 points (13) as well as AFP level irrespective of tumor burden (14).”
InfluentialHara, K., Takeda, A., Tsurugai, Y., Saigusa, Y., Sanuki, N., Eriguchi, T., Maeda, S., Tanaka, K., & Numata, K. (2019) · Hepatology · doi:10.1002/hep.30591 · Cited by 164 · cited 1×
“According to several retrospective studies, stereotactic body radiation therapy (SBRT) showed comparable survival benefit with radiofrequency ablation (RFA) for early-stage HCC (55,56).”
Shimamura, T., Akamatsu, N., Fujiyoshi, M., Kawaguchi, A., Morita, S., Kawasaki, S., Üemoto, S., Kokudo, N., Hasegawa, K., Ohdan, H., et al. (2018) · Transplant International · doi:10.1111/tri.13391 · Cited by 163 · cited 1×
“The 5-5-500 criteria ( ≤ 5 cm, ≤ 5 tumors, AFP ≤ 500 ng/mL) has been adopted as additional criteria to Milan criteria for insurance coverage in Japan since 2019 (49,50) .”
Qin, S., Finn, R. S., Kudo, M., Meyer, T., Vogel, A., Ducreux, M. P., Macarulla, T. M., Tomasello, G., Boisserie, F., Hou, J. W.-S., et al. (2019) · Future Oncology · doi:10.2217/fon-2019-0097 · Cited by 153
Reig, M., Darnell, A., Forner, A., Rimola, J., Ayuso, C., & Bruix, J. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1394143 · Cited by 149 · cited 1×
“…range of effective systemic therapies, patients who experience Untreatable Progression (UTP) under TACE defined as failure of TACE (63) by the BCLC group, or TACE refractoriness defined as no response after two TACE sessions (64) by the JSH are recommended to switch to systemic therapies (65).”
Kudo, M., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D. H., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.009 · Cited by 146
Kudo, M., Ueshima, K., Ikeda, M., Torimura, T., Tanabe, N., Aikata, H., Izumi, N., Yamasaki, T., Nojiri, S., Hino, K., et al. (2022) · Liver Cancer · doi:10.1159/000522547 · Cited by 141 · cited 2×
“…to the TACTICS trial which adapted the criteria of progression as time to UTP or to TACE refractoriness, sorafenib plus TACE was associated with a significant improvement in PFS (22.8 vs. 13.5 months, P=0.020) and a prolonged interval (21.1 vs. 16.9 weeks, p=0.018) between TACE sessions (71,72) .”
InfluentialSchnitzbauer, A. A., Filmann, N., Adam, R., Bachellier, P., Bechstein, W. O., Becker, T., Bhoori, S., Bilbao, I., Brockmann, J., Burra, P., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004280 · Cited by 139 · cited 1×
“…therapies via locoregional therapies to reduce tumor burden to within the Milan criteria have yielded favorable long-term outcomes (51,53) . mTOR-inhibitor treatment with sirolimus for ≥ 3 months are recommended to prolong post-LT PFS and OS, especially for those with AFP ≥ 10 ng/mL (54).”
Chen, M., Cao, J., Hu, J., Topatana, W., Li, S., Juengpanich, S., Lin, J., Tong, C., Shen, J., Zhang, B., et al. (2021) · Liver Cancer · doi:10.1159/000512028 · Cited by 138 · cited 1×
“…peritumoral radiomic signature (TPR-signature) in combination with clinical parameters including AFP, BCLC subclassification, tumor location and arterial hyperenchancement comprising a clinical-radiomic (CR) model can be served a robust tool to predict response to the first session of TACE (62).”
Han, G., Berhane, S., Toyoda, H., Bettinger, D., Elshaarawy, O., Chan, A. W. H., Kirstein, M., Mosconi, C., Hucke, F., Palmer, D., et al. (2020) · Hepatology · doi:10.1002/hep.31022 · Cited by 133 · cited 1×
“…scoring system (60), “Pre-TACE-Predict” model using tumor number, size, AFP, albumin, bilirubin, vascular invasion and etiology, and “Post-TACE-Predict” model using number, size, AFP, bilirubin, vascular invasion and imaging response are proposed to predict the efficacy of TACE (61).”
Wang, Z., Peng, Y., Hu, J., Wang, X., Sun, H., Sun, J., Shi, Y., Xiao, Y., Ding, Z.-B., Yang, X., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002942 · Cited by 128 · cited 1×
“Recent studies recommend ALPPS over PVE in faster introduction of liver regeneration and fewer risk of tumor progression (34,35) .”
Self-citationFan, J., Yang, G.-S., Fu, Z., Peng, Z., Xia, Q., Peng, C.-H., Qian, J.-M., Zhou, J., Xu, Y., Qiu, S., et al. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0584-6 · Cited by 112 · cited 1×
“The expansion of criteria for liver transplantation (LT) beyond Milan criteria has been practiced with favorable survival results in China for years (41,42).”
Self-citationXu, Q., Kobayashi, S., Ye, X., & Xia, M. (2014) · Scientific Reports · doi:10.1038/srep07252 · Cited by 111 · cited 1×
“The JSH recommend either hepatectomy or ablation for patients with 1–3 tumors and tumor size ≤ 3 cm due to comparable recurrence-free survival (RFS) from the SURF trial (17), however, the Chinese experts prefer hepatectomy over ablation considering better overall survival (OS) (18).”
Informative censoring — a neglected cause of bias in oncology trials
Templeton, A. J., Amir, E., & Tannock, I. F. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0368-0 · Cited by 106 · cited 1×
“…of a broad range of effective systemic therapies, patients who experience Untreatable Progression (UTP) under TACE defined as failure of TACE (63) by the BCLC group, or TACE refractoriness defined as no response after two TACE sessions (64) by the JSH are recommended to switch to systemic…”
Kurebayashi, Y., Matsuda, K., Ueno, A., Tsujikawa, H., Yamazaki, K., Masugi, Y., Kwa, W. T., Effendi, K., Hasegawa, Y., Yagi, H., et al. (2021) · Hepatology · doi:10.1002/hep.32201 · Cited by 106
Pung, L., Ahmad, M. U., Mueller, K., Rosenberg, J., Stave, C. D., Hwang, G. L., Shah, R. P., & Kothary, N. (2017) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2016.11.037 · Cited by 91 · cited 1×
“Technically, super-selective TACE with the assistance of Cone-Beam CT if necessary is emphasized to guarantee the efficacy of TACE in the updated guidelines (58,59).”
Li, B., Qiu, J., Zheng, Y., Shi, Y., Zou, R., He, W. A., Yuan, Y., Zhang, Y., Wang, C., Qiu, Z., et al. (2021) · Annals of Surgery Open · doi:10.1097/as9.0000000000000057 · Cited by 79 · cited 6×
“On the other hand, FOLFOX-HAIC developed in China was associated with a prolonged mOS (14.5 vs. 7.0 months, P 0.001) compared to sorafenib for locally advanced HCC (75) .”
InfluentialKondo, M., Morimoto, M., Kobayashi, S., Ohkawa, S., Hidaka, H., Nakazawa, T., Aikata, H., Hatanaka, T., Takizawa, D., Matsunaga, K., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6198-8 · Cited by 79
Miyayama, S., & Matsui, O. (2016) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2016.04.014 · Cited by 72 · cited 1×
“Technically, super-selective TACE with the assistance of Cone-Beam CT if necessary is emphasized to guarantee the efficacy of TACE in the updated guidelines (58,59).”
Kudo, M. (2018) · Liver Cancer · doi:10.1159/000492533 · Cited by 69 · cited 1×
“For TACE-unsuitable HCC, the JSH recommend a lenvatinib-TACE sequential therapy based on a proof-of-concept study (66,67).”
Llovet, J. M., Shepard, K., Finn, R., Ikeda, M., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz247.073 · Cited by 67 · cited 1×
“On the other hand, lenvatinib plus pembrolizumab with encouraging results in the Ib study continued to render favorable OS benefit as first-line therapy for advanced HCC in the phase III LEAP-002 study (82,83) .”
Byun, H. K., Kim, H. J., Im, Y. R., Kim, D. Y., Han, K., & Seong, J. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.12.025 · Cited by 59 · cited 1×
“…(HAIC) using oxaliplatin, fluorouracil, and leucovorin regimen (FOLFOX-HAIC), or TACE plus FOLFOX-HAIC (28), radiation plus fluorouracil-HAIC (29), and systemic therapies in combination with FOLFOX-HAIC (30) or TACE (31) have been explored as conversion therapies to induce tumor shrinkage or…”
El-Khoueiry, A. B., Yau, T. C. C., Kang, Y., Kim, T., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M., Matilla, A. M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.3_suppl.269 · Cited by 51 · cited 1×
“Besides, nivolumab plus ipilimumab with an ORR of 32% and a mOS of 22.8 months is also recommended as second-line treatment by the NCCN panel (91).”
InfluentialXie, D., Sun, Q., Wang, X., Zhou, J., Fan, J., Ren, Z., & Gao, Q. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7037 · Cited by 48 · cited 1×
“With encouraging results from phase II studies (25-27) or real world practices (92), current Chinese guidelines recommend the integration of systemic therapies with local therapies, albeit the strength of the recommendation is rated as moderate.”
Self-citationIndicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients
Li, J. H., Yan, L., Yang, J., Chen, Z., Li, B., Zeng, Y., Wen, T., Zhao, J., Wang, W., Yang, J., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4170 · Cited by 42 · cited 1×
“The expansion of criteria for liver transplantation (LT) beyond Milan criteria has been practiced with favorable survival results in China for years (41,42).”
Li, P.-P., Huang, G., Jia, N., Pan, Z., Liu, H., Yang, Y. N., He, C.-J., Lau, W. Y., Yang, Y., & Zhou, W. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-20-264 · Cited by 41
Lee, S., Kim, K. W., Song, G., Kwon, J. H., Hwang, S., Kim, K., Ahn, C., Moon, D., Park, G., & Lee, S. (2020) · Liver Cancer · doi:10.1159/000507887 · Cited by 33 · cited 2×
“For patients on the waiting list for LT, the efficacy of bridging therapies via locoregional or systemic therapies to prevent tumor progression remains controversial (51,52).”
Kudo, M., Hasegawa, K., Kawaguchi, Y., Takayama, T., Izumi, N., Yamanaka, N., Shimada, M., Inomata, M., Kaneko, S., Baba, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.4093 · Cited by 32 · cited 1×
“The JSH recommend either hepatectomy or ablation for patients with 1–3 tumors and tumor size ≤ 3 cm due to comparable recurrence-free survival (RFS) from the SURF trial (17), however, the Chinese experts prefer hepatectomy over ablation considering better overall survival (OS) (18).”
Ducreux, M. P., Abou‐Alfa, G. K., Ren, Z., Edeline, J., Li, Z., Assénat, E., Rimassa, L., Blanc, J. F., Ross, P. J., Fang, W. J., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.005 · Cited by 31 · cited 1×
“Apart from regorafenib, targeted agent apatinib (80) and PD-1 inhibitors camrelizumab (85) and tislelizumab (86,87) are added as second-line systemic therapies for patients who progressed on sorafenib in the 2022 Chinese guidelines.”
Self-citationLiu, D., Mu, H., Liu, C., Zhang, W., Cui, Y., Wu, Q., Zhu, X., Fang, F., Zhang, W., Xing, W., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.4073 · Cited by 17
Ferrer, J., Sampson, J., Forner, A., Sapena, V., Díaz, A., Vilana, R., Navasa, M., Fondevila, C., Miquel, R., Ayuso, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.015 · Cited by 16 · cited 1×
“There is a growing global consensus on that a minor increase in tumor size and number beyond Milan criteria does not withdraw the long-term survival benefit of LT (44-46).”
Zhang, W., Lu, S., Hu, B., Wan, T., Wang, H., Han, J. S., Zhang, Z., Cao, J., Xin, X., Pan, Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.e16173 · Cited by 14
Shinkawa, H., Tanaka, S., Takemura, S., Amano, R., Kimura, K., Kinoshita, M., Miyazaki, T., & Kubo, S. (2020) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.792 · Cited by 13 · cited 1×
“The 5-5-500 criteria ( ≤ 5 cm, ≤ 5 tumors, AFP ≤ 500 ng/mL) has been adopted as additional criteria to Milan criteria for insurance coverage in Japan since 2019 (49,50) .”
Zhang, X., Zhu, X., Liu, C., Lu, W., Li, Q., Chen, W., Li, Z., Lü, Q., Peng, W. J., Li, C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.453 · Cited by 13 · cited 1×
“…using oxaliplatin, fluorouracil, and leucovorin regimen (FOLFOX-HAIC), or TACE plus FOLFOX-HAIC (28), radiation plus fluorouracil-HAIC (29), and systemic therapies in combination with FOLFOX-HAIC (30) or TACE (31) have been explored as conversion therapies to induce tumor shrinkage or downstaging.”
Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma
Kwong, A. J., & Mehta, N. J. (2020) · Clinics in Liver Disease · doi:10.1016/j.cld.2020.08.002 · Cited by 12
Wang, L., Wang, H., Cui, Y., Jin, K., Liu, W., Wang, K., & Xing, B. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.449 · Cited by 11
Li, S., Mei, J., Cheng, Y., Li, Q., Wang, Q., Fang, C., Lei, Q., Huang, H., Cao, M., Luo, R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.4013 · Cited by 4
Cited by
Wang, L., Tian, F., Li, C., Wang, J., Dong, J., Cai, J., Yang, S., & Feng, X. (2025) · Patterns · doi:10.1016/j.patter.2025.101364 · Cited by 11
Metadata
- Authors
- Xie, D.-Y., Zhu, K., Ren, Z.-G., Zhou, J., Fan, J., & Gao, Q.
- Venue
- Hepatobiliary Surgery and Nutrition
- Publisher
- AME Publishing Company
- Published
- 2023-04
- Volume
- 12
- Issue
- 2
- Pages
- 216-228
- ISSN
- 2304-3881 (ISSN-L)
- 2304-389X
- OpenAlex
- W4323057661
- Cited by
- 162
- References
- 95
- FWCI
- 22.93
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.